Volume 1.14 | Apr 23

Prostate Cell News 1.14, April 23, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


MU Researchers Show Potential for New Cancer Detection and Therapy Method
Scientists explain how engineered gold nanoparticles tied to a cancer-specific receptor could be targeted to tumor cells to treat prostate, breast or lung cancers in humans. [Press release from University of Missouri discussing the online prepublication in Proceedings of the National Academy of Sciences U S A]

Watch Procedure Now  
Detect 7x More Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies


Idaho State University Study Suggests Pollutants, Not Weather, Cause Increased Prostate Cancer in Northerners
The correlation between cold dry weather and an increased incidence of prostate cancer may be due to the effects of weather on pollutants.  Researchers suggest this pattern may be because organic pollutants, including some pesticides, precipitate out of the atmosphere at colder temperatures and thus may result in higher incidences of prostate cancer. [Press release from Idaho State University discussing the online prepublication in International Journal of Health Geographics]

Targeting Drugs for Cell Division Pathway in Prostate Tumors Paves Way for Clinical Trials
Trying to break down a barrier that prevents effective treatment of prostate cancer, researchers have identified candidate drugs that block a key protein responsible for tumor growth. [The Cancer Institute of New Jersey Press Release]

AACR: Drug Combo Effective in Cancer Models
A thalidomide analogue called lenalidomide (Revlimid), combined with the taxane docetaxel (Taxotere), may improve survival in cell and animal models of hormone-resistant metastatic prostate cancer, a British researcher reported. [MedPage Today Press Release]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies



Bombesin Functionalized Gold Nanoparticles Show In Vitro and In Vivo Cancer Receptor Specificity
Bombesin (BBN) peptides have demonstrated high affinity toward gastrin-releasing peptide (GRP) receptors in vivo that are overexpressed in prostate, breast, and small-cell lung carcinoma. Researchers have synthesized a library of GRP receptor-avid nanoplatforms by conjugating gold nanoparticles with BBN peptides. [Proc Natl Acad Sci U S A]

In situ Vaccination Combined with Androgen Ablation and Regulatory T Cell Depletion Reduces Castration-Resistant Tumor Burden in Prostate-Specific Pten Knockout Mice
Because immunotherapeutic efficacy is determined by the balance of immune cell subsets and their location within the tumor, researchers assessed the acute and chronic effect of androgen ablation on the localization of T cell subsets within castration-resistant murine prostate cancer. [Cancer Res]

Mechanism of Autophagy to Apoptosis Switch Triggered in Prostate Cancer Cells by Antitumor Cytokine Melanoma Differentiation-Associated Gene 7/Interleukin-24
Here, researchers report that adenoviral-mediated delivery of melanoma differentiation-associated gene 7 (Ad.mda-7)-induced endoplasmic reticulum stress and ceramide production trigger autophagy in human prostate cancer cells, but not in normal prostate epithelial cells, through a canonical signaling pathway that involves Beclin-1, atg5, and hVps34. [Cancer Res]

PAK4: A Pluripotent Kinase That Regulates Prostate Cancer Cell Adhesion
Researchers report that DU145 human prostate cancer cells with reduced levels of p21-activated kinase 4 (PAK4) expression are unable to successfully migrate in response to hepatocyte growth factor, have prominent actin stress fibres, and an increase in the size and number of focal adhesions. [J Cell Sci]

MiR-148a Attenuates Paclitaxel-Resistance of Hormone-Refractory, Drug-Resistant Prostate Cancer PC3 Cells by Regulating MSK1 Expression
In this report, researchers showed that miR-148a expression levels were lower in PC3 and DU145 hormone-refractory prostate cancer cells in comparison to PrEC normal human prostate epithelial cells and LNCaP hormone-sensitive prostate cancer cells. [J Biol Chem]

Targeted Knockdown of SEPT9_v1 Inhibits Tumor Growth and Angiogenesis of Human Prostate Cancer Cells Concomitant with Disruption of Hypoxia-Inducible Factor-1 Pathway
The results provide new insights and validation for applying septin 9 transcript variant 1 (SEPT9_v1) as a potential target for antitumor therapy by interrupting the hypoxia-inducible factor-1 pathway.  [Mol Cancer Res]


Hospital Characteristics, Clinical Severity, and Outcomes for Surgical Oncology Patients
The objective was to determine whether differences in outcomes explained by hospital structural characteristics are mitigated by differences in patient severity. [Surgery]

Factors Associated with Initial Treatment and Survival for Clinically Localized Prostate Cancer: Results From the CDC-NPCR Patterns of Care Study (PoC1)
The purpose of this study was to describe the initial treatment patterns for localized prostate cancer in a population-based sample and to determine the clinical and patient characteristics associated with initial treatment and overall survival. [BMC Cancer]

A Phase I Clinical Study of High Dose Ketoconazole Plus Weekly Docetaxel for Metastatic Castration Resistant Prostate Cancer
This phase I study of high dose ketoconazole and docetaxel was designed against castration resistant prostate cancer to determine the maximum tolerated doses, side effects, and pharmacokinetic interaction of co-administered docetaxel and ketoconazole. [J Urol]


Amgen’s First Quarter 2010 Adjusted Earnings Per Share Increased 20 Percent to $1.30
Amgen reported adjusted earnings per share of $1.30 for the first quarter of 2010, an increase of 20 percent compared to $1.08 for the first quarter of 2009. Adjusted net income increased 14 percent to $1,282 million for the first quarter of 2010 compared to $1,120 million for the first quarter of 2009. [Amgen Inc., Press Release]

Diagnocure’s PCA3 Test at the Forefront of the Management of Prostate Cancer
DiagnoCure, Inc. announced that its proprietary prostate cancer biomarker PCA3 was the topic of over 13 presentations at the 2010 European Association of Urology (EAU) meeting. [DiagnoCure, Inc. Press Release]

A Shot in the Arm for Cancer Vaccines?
Now, after some 20 years of successes and setbacks, Dendreon’s prostate-cancer vaccine Provenge (sipleucel-T) may finally be nearing the market; the US Food and Drug Administration is expected to reach a decision on its approval by 1 May. [Nature News]

Seattle Genetics and Agensys, an Affiliate of Astellas, Report ASG-5ME Preclinical Data at AACR
Seattle Genetics, Inc. and Agensys, Inc. reported preclinical data with ASG-5ME, an antibody-drug conjugate that is being co-developed by both companies for the treatment of solid tumors. [The Wall Street Journal]


Patents Block Competition, Slow Innovation in Gene Testing
Exclusive licenses to gene patents, most of which are held by academic institutions and based on taxpayer-funded research, do more to block competition in the gene testing market than to spur the development of new technologies for gauging disease risk. [Duke University Press Release]

Policy Reminder Concerning Appendix Materials for All National Institutes of Health/Agency for Healthcare Research and Quality/National Institute for Occupational Safety and Health Grant Applications (NOT-OD-10-077) [National Institutes of Health, United States]

Enhancing Peer Review: Clarification of Resubmission Policy and Determination of New Application Status (NOT-OD-10-080) [National Institutes of Health, United States]

Guidance on Confirming Appropriate Charges to NIH Awards During Periods of Noncompliance for Activities Involving Animals (NOT-OD-10-081) [National Institutes of Health, United States]

Update of Sample Animal Welfare Assurance for Foreign Institutions (NOT-OD-10-083) [National Institutes of Health, United States]

Agency for Healthcare Research and Quality Small Research Grant Program (R03) (PAR-10-168) [National Institutes of Health, United States]


American Urological Association (AUA) 2010 Annual Meeting
May 29-June 3, 2010
San Francisco, United States

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

21st Meeting of the European Association for Cancer Research (EACR) 
June 26-29, 2010
Oslo, Norway

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
August 23-27, 2010
Toronto, Canada

28th World Congress of Endourology and SWL
September 1-4, 2010
Chicago, United States

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Sr. Product Support and Training Specialist (CardianBCT)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us